Who is sponsoring NCT05483257?

NCT05483257 is sponsored by BAIYONG SHEN.

What drugs are being tested in NCT05483257?

Interventions in NCT05483257: Multigene panel for next-generation sequencing.

What condition does NCT05483257 study?

NCT05483257 studies Pancreatic Cancer Resectable.

Is NCT05483257 still recruiting?

NCT05483257 is currently completed. Last updated 2 August 2022.

Last reviewed 2022-08-02 · How we verify

NCT05483257

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic Adenocarcinoma

Completed Last updated 2 August 2022

What this trial tests

trial testing Multigene panel for next-generation sequencing in Pancreatic Cancer Resectable in 226 participants. Completed in 13 September 2021.

Timeline

14 March 2018

Primary endpoint
3 August 2020

13 September 2021

Quick facts

Lead sponsor	BAIYONG SHEN
Status	Completed
Study type	OBSERVATIONAL
Enrollment	226
Start date	14 March 2018
Primary completion	3 August 2020
Estimated completion	13 September 2021
Sites	1 location across China

Drugs / interventions tested

Multigene panel for next-generation sequencing

Conditions studied

Pancreatic Cancer Resectable — all drugs for Pancreatic Cancer Resectable →

Sponsor

BAIYONG SHEN

Who can join

Adults 34 to 84, any sex, with Pancreatic Cancer Resectable. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pancreatic adenocarcinoma (PAAD) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. Given the potential associations of human leukocyte antigen class I (HLA-I) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential HLA-I genotype could predict the postoperative outcomes in resected PAAD patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study.
Wen C, Zhang L, Yang Y, Jin Y, et al · · 2023 · cited 2× · PMID 37026827 · DOI 10.1097/js9.0000000000000264

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer Resectable

Currently open trials in the same condition.

NCT07326150 — Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Canc · active not recruiting
NCT07081360 — Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer · Phase 3 · recruiting
NCT06914349 — Antecolic Versus Retrocolic Gastrojejunostomy During Whipple's Procedure · NA · recruiting
NCT07157605 — Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID) · recruiting
NCT06722911 — Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05483257 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BAIYONG SHEN
Last refreshed: 2 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05483257.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing